Fortrea Holdings (FTRE) Receivables - Net (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Receivables - Net came in at $654.4 million in Q2 2026, down 11.47% YoY from $739.2 million in Q2 2025, and up 5.62% on a QoQ basis from $619.6 million in Q1 2026.
Fortrea Holdings (FTRE) Receivables - Net (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Receivables - Net data on file, last reported at $654.4 million in Q2 2026.
- Quarterly Receivables - Net fell 11.47% year-over-year to $654.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $654.4 million (down 11.47% YoY) and the FY2025 annual result came in at $589.7 million, down 10.58% from the prior year.
- Receivables - Net grew to $654.4 million in Q2 2026, from $619.6 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $1.0 billion in Q3 2023 to a low of $589.7 million in Q4 2025.
- A 5-year average of $785.4 million and a median of $709.0 million in 2024 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2024 — Receivables - Net tumbled 37.13% — and 2025, when it gained 15.88%.
- Tracing FTRE's Receivables - Net over 5 years: stood at $1.0 billion in 2022, then dropped by 3.3% to $988.5 million in 2023, then slumped by 33.28% to $659.5 million in 2024, then retreated by 10.58% to $589.7 million in 2025, then gained by 10.97% to $654.4 million in 2026.
- The last three Receivables - Net figures came in at $654.4 million (Q2 2026), $619.6 million (Q1 2026), and $589.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 654.40 Mn |
| Jun 30, 2026 | 654.40 Mn |
| Mar 31, 2026 | 619.60 Mn |
| Mar 31, 2026 | 619.60 Mn |
| Dec 31, 2025 | 589.70 Mn |
| Dec 31, 2025 | 589.70 Mn |
| Sep 30, 2025 | 663.20 Mn |
| Sep 30, 2025 | 663.20 Mn |
| Jun 30, 2025 | 739.20 Mn |
| Jun 30, 2025 | 739.20 Mn |
| Mar 31, 2025 | 729.00 Mn |
| Mar 31, 2025 | 729.00 Mn |
| Dec 31, 2024 | 659.50 Mn |
| Dec 31, 2024 | 659.50 Mn |
| Sep 30, 2024 | 689.10 Mn |
| Sep 30, 2024 | 689.10 Mn |
| Jun 30, 2024 | 637.90 Mn |
| Jun 30, 2024 | 637.90 Mn |
| Mar 31, 2024 | 941.00 Mn |
| Mar 31, 2024 | 941.00 Mn |